Related references
Note: Only part of the references are listed.Acalabrutinib in treatment-naive chronic lymphocytic leukemia
John C. Byrd et al.
BLOOD (2021)
Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients
Daan C. H. van Dorst et al.
CIRCULATION RESEARCH (2021)
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
Richard R. Furman et al.
LEUKEMIA (2021)
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association
Salim S. Virani et al.
CIRCULATION (2020)
Acalabrutinib plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
Jennifer A. Woyach et al.
CANCER DISCOVERY (2020)
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Paolo Ghia et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease The ARIC Study
Ning Ding et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase
Ling Xiao et al.
CIRCULATION (2020)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Hypertension and incident cardiovascular events following ibrutinib initiation
Tyler Dickerson et al.
BLOOD (2019)
Cardiovascular Toxicities Associated With Ibrutinib
Joe-Elie Salem et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
Lindsey E. Roeker et al.
JAMA NETWORK OPEN (2019)
Hypertension in Cancer Patients and Survivors Epidemiology, Diagnosis, and Management
Jordana B. Cohen et al.
JACC: CARDIOONCOLOGY (2019)
High incidence of atrial fibrillation in patients treated with ibrutinib
Florian Baptiste et al.
OPEN HEART (2019)
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Michael Wang et al.
LANCET (2018)
Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies
Avirup Guha et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Sarah E. M. Herman et al.
CLINICAL CANCER RESEARCH (2017)
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
Viralkumar Patel et al.
CLINICAL CANCER RESEARCH (2017)
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
Tracy E. Wiczer et al.
BLOOD ADVANCES (2017)
Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells
Gayathri Natarajan et al.
ONCOIMMUNOLOGY (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Increased Nitric Oxide Bioavailability and Decreased Sympathetic Modulation Are Involved in Vascular Adjustments Induced by Low-Intensity Resistance Training
Fabricio N. Macedo et al.
FRONTIERS IN PHYSIOLOGY (2016)
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Jackson T. Wright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) (vol 311, pg 507, 2014)
P. A. James
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)
Paul A. James et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
A risk score for predicting near-term incidence of hypertension: The Framingham Heart Study
Nisha I. Parikh et al.
ANNALS OF INTERNAL MEDICINE (2008)
Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
V Schächinger et al.
CIRCULATION (2000)
Share Paper
